Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kiniksa Pharmaceuticals Ltd.

www.kiniksa.com

Latest From Kiniksa Pharmaceuticals Ltd.

Galderma’s First-In-Class Biologic Chases Eczema Spoils

Galderma’s novel biologic is heading for Phase III studies in moderate-to-severe atopic dermatitis as the race to join Dupixent in an expanding market hots up.

Clinical Trials Dermatology

Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019

Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.

Financing Business Strategies

Start-Up Quarterly Statistics: A Record-Breaking Q2 As Financings Surge

Biopharma start-ups had a record-breading quarter in terms of fundraising. A review of biopharma start-up deal-making and financing activity from April through June 2018, based on data from Strategic Transactions.

Financing StartUps and SMEs

IPO Update: Returns Rebound As June Sees Its First New Biopharma Offering

MeiraGTx was the first to go public in the US in June after six drug developer IPOs launched in May. With returns for this year's first-time biopharma offerings more than doubling from 9% at the end of April to 23.6% as of June 8, four new companies have filed and six have set terms for future IPOs.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Dermatology
  • Immune Disorders
  • Inflammation
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Kiniksa Pharmaceuticals Ltd.
  • Senior Management
  • Sanj Patel, CEO
    Chris Heberlig, CFO
    Stephen Mahoney, Pres. & COO
    John Paolini, MD, PhD, CMO
    Eben Tessari, CBO
  • Contact Info
  • Kiniksa Pharmaceuticals Ltd.
    Phone: (781) 431-9100
    100 Hayden Ave.
    Lexington, MA 02421
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register